158 related articles for article (PubMed ID: 15712660)
1. Effect of ursodeoxycholic acid on granulomatous liver disease due to sarcoidosis.
Alenezi B; Lamoureux E; Alpert L; Szilagyi A
Dig Dis Sci; 2005 Jan; 50(1):196-200. PubMed ID: 15712660
[No Abstract] [Full Text] [Related]
2. Effect of ursodeoxycholic acid on chronic intrahepatic cholestasis due to sarcoidosis.
Bécheur H; Dall'osto H; Chatellier G; Charton-Bain MC; Aubertin JM; Attar A; Bloch F; Petite JP
Dig Dis Sci; 1997 Apr; 42(4):789-91. PubMed ID: 9125650
[No Abstract] [Full Text] [Related]
3. [Usefulness of ursodeoxycholic acid in a case of hepatic sarciodosis].
Saito A; Takano M; Kaise S; Utsumi Y; Gunji N; Ishihata R; Irisawa A; Ohira H
Nihon Shokakibyo Gakkai Zasshi; 2010 Apr; 107(4):632-8. PubMed ID: 20379098
[TBL] [Abstract][Full Text] [Related]
4. Sarcoidosis and the Liver.
Kumar M; Herrera JL
Clin Liver Dis; 2019 May; 23(2):331-343. PubMed ID: 30947880
[TBL] [Abstract][Full Text] [Related]
5. The effect of ursodeoxycholic acid in cystic cholangiopathies.
Lammert F; Méndez-Sánchez N
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):949-950. PubMed ID: 27740534
[No Abstract] [Full Text] [Related]
6. [New aspects of pharmacological effects of ursodeoxycholic acid].
Radchenko VG; Seliverstov PV; Sitkin SI
Eksp Klin Gastroenterol; 2014; (8):4-10. PubMed ID: 25911905
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review.
Cheng K; Ashby D; Smyth R
J R Soc Med; 1997; 90 Suppl 31(Suppl 31):6-12. PubMed ID: 9204005
[No Abstract] [Full Text] [Related]
8. [The characteristics of the use of ursodeoxycholic acid in chronic diseases of the hepatobiliary system].
Dehtiar'ova II; Chernenko VV; Anokhina HA; Opanasiuk ND; Pavlik-Novol's'kyĭ T; Haĭsenko AV
Lik Sprava; 1995; (9-12):47-8. PubMed ID: 8983789
[No Abstract] [Full Text] [Related]
9. Sarcoidosis of the liver: to treat or not to treat?
Bakker GJ; Haan YC; Maillette de Buy Wenniger LJ; Beuers U
Neth J Med; 2012 Oct; 70(8):349-56. PubMed ID: 23065982
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
Serfaty L; Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
[No Abstract] [Full Text] [Related]
11. [In process].
Vollmer H
Med Monatsschr Pharm; 2017 Mar; 40(3):131. PubMed ID: 29952486
[No Abstract] [Full Text] [Related]
12. [Hepatobiliary lesions in Crohn's disease and conservative methods of treatment].
Grigor'eva GA; Meshalkina NIu
Eksp Klin Gastroenterol; 2013; (6):3-6. PubMed ID: 24772851
[No Abstract] [Full Text] [Related]
13. Ursodeoxycholic acid in the treatment of liver diseases.
Saksena S; Tandon RK
Postgrad Med J; 1997 Feb; 73(856):75-80. PubMed ID: 9122101
[TBL] [Abstract][Full Text] [Related]
14. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
15. Should we treat cholestatic liver disease with cholesterol synthesis inhibitors?
Schmidt HH; Manns MP
Am J Gastroenterol; 1996 Feb; 91(2):406-7. PubMed ID: 8607528
[No Abstract] [Full Text] [Related]
16. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
17. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
Olsson R
Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
[TBL] [Abstract][Full Text] [Related]
18. [Granulomatous hepatitis successfully treated with ursodeoxycholic acid].
Németh E; Bugovics E; Lengyel G; Pécsi G; Schaff Z; Fehér J
Orv Hetil; 2006 Aug; 147(31):1465-70. PubMed ID: 16981420
[TBL] [Abstract][Full Text] [Related]
19. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.
Colombo C; Crosignani A; Battezzati PM; Castellani MR; Comi S; Melzi ML; Giunta A
J Hepatol; 1999 Oct; 31(4):672-7. PubMed ID: 10551391
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid for cystic fibrosis-related liver disease.
Cheng K; Ashby D; Smyth R
Cochrane Database Syst Rev; 2000; (2):CD000222. PubMed ID: 10796703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
